TP53 and lung carcinoma: As a result, this antimiR could be investigated in lung cancer clinical trial, either alone or in conjunction with other drugs, to up-regulate the expression of the p53 regulator of cell cycle utilizing a targeting moiety, as it has previously been demonstrated to be effective in other cancer treatments.